Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-02-28 01:19Financial Data Summary - The company reported a preliminary net loss attributable to the parent company of approximately -79,798.56 million RMB, a decrease in loss of about 37.70% compared to the previous year [5] - The net loss attributable to the parent company, excluding non-recurring gains and losses, is expected to be around -91,246.08 million RMB, reflecting a decrease in loss of approximately 29.26% year-on-year [5] Business Performance and Financial Condition - The core product, Toripalimab injection (brand name: Tuoyi), saw a significant sales revenue increase of approximately 37.72% year-on-year in the domestic market [2] - As of the announcement date, Tuoyi has been included in the national medical insurance catalog for all 12 approved indications, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [2] - The company is expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Australia, and Singapore [2] Operational Strategy - The company is implementing a "quality improvement and efficiency enhancement" action plan, which has led to a significant narrowing of net losses compared to the previous year while maintaining efficient progress on its core pipeline [3] - The company is advancing several innovative drugs with international market competitiveness, including JS207 (a PD-1/VEGF dual antibody), JS212 (an EGFR/HER3 ADC), and JS213 (a PD-1/IL-2 fusion protein), with ongoing clinical trials exploring various combination therapies [3][4] - The company is focused on cost control and resource allocation while maintaining high efficiency in its core pipeline, which has contributed to a reduction in losses [4]